{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:20:24Z","timestamp":1790864424916,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>INTRODUCTION<\/jats:title><jats:p>In EMERGE (NCT02484547), participants receiving aducanumab had significantly less progression versus placebo on all prespecified clinical endpoints at week 78. Here, we explicate the clinical meaningfulness of these treatment effects by analyzing item\u2010level data and the persistence of treatment benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Participants with early Alzheimer's disease (AD) were stratified by apolipoprotein E (<jats:italic>APOE<\/jats:italic>) \u03b54 status and randomized (1:1:1) to receive low\u2010 or high\u2010dose aducanumab, or placebo. Prespecified principal component analyses (PCAs) per the Statistical Analysis Plan were followed by post hoc examination of individual domains\/items across all five clinical endpoints. Progression analysis assessed reduction in clinical decline.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>High\u2010dose aducanumab demonstrated clinically meaningful slowing of progression across clinical endpoints measuring cognition, daily function, and behavioral symptoms. Delay of progression over 18 months was consistent across measures; treatment effects increased over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>DISCUSSION<\/jats:title><jats:p>Across multiple analyses aducanumab slowed cognitive decline, prolonged functional independence, and attenuated behavioral symptoms in participants with early AD. These outcomes comprise the elements of a clinically meaningful response to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Highlights<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Endpoints in EMERGE assessed different aspects of cognition, daily function, and behavioral symptoms.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Treatment benefits were observed across subdomains on all five clinical endpoints.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Aducanumab meaningfully slowed disease progression in participants with early AD.<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1002\/alz.70224","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T23:35:27Z","timestamp":1750635327000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease"],"prefix":"10.1002","volume":"21","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[{"name":"University of Las Vegas, UNLV  Las Vegas NV USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Cohen","sequence":"additional","affiliation":[{"name":"Toronto Memory Program  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Murphy","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly M.","family":"Brothers","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Nejati","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Forrestal","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"de Moor","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O'Gorman","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Harrison","sequence":"additional","affiliation":[{"name":"Alzheimercentrum AUmC  Amsterdam the Netherlands"},{"name":"Scottish Brain Sciences  Edinburgh UK"},{"name":"Institute of Psychiatry Psychology &amp; Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Jaeger","sequence":"additional","affiliation":[{"name":"CognitionMetrics LLC  Stamford Connecticut USA"},{"name":"Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Jane","family":"Mummery","sequence":"additional","affiliation":[{"name":"Dementia Research Centre Queen Square Institute of Neurology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton P.","family":"Porsteinsson","sequence":"additional","affiliation":[{"name":"University of Rochester School of Medicine and Dentistry  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Potashman","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tian","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"He","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha Budd","family":"Haeberlein","sequence":"additional","affiliation":[{"name":"Biogen  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_8_3_1","unstructured":"Aduhelm (aducanumab\u2010avwa).Prescribing information. Biogen Inc;2021. Accessed [July 27 2021]."},{"key":"e_1_2_8_4_1","article-title":"Building clinically relevant outcomes across the Alzheimer's disease spectrum","volume":"7","author":"Rentz DM","year":"2021","journal-title":"Alzheimers Dement"},{"key":"e_1_2_8_5_1","unstructured":"LeberP Guidelines for the Clinical Evaluation of antiDementia Drugs (1990 draft).1990."},{"key":"e_1_2_8_6_1","unstructured":"US Food and Drug Administration.Early Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry. Guidance Compliance Regulatory Information.2024."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.129"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00445-0"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00659-6"},{"key":"e_1_2_8_12_1","unstructured":"US Food and Drug Administration.Early Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry.Guidance Compliance Regulatory Information.2018."},{"key":"e_1_2_8_13_1","unstructured":"European Medicines Agency.Revised guideline on clinical studies for Alzheimer's disease medicines.CHMP.2018."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00443-2"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1302513"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00003"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00005"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13755"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170991"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00273-0"},{"key":"e_1_2_8_26_1","first-page":"109","article-title":"Defining disease modifying therapy for Alzheimer's disease","volume":"4","author":"Cummings J","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_8_27_1","article-title":"Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: open peer commentary","volume":"9","author":"Cummings J","year":"2023","journal-title":"Alzheimers Dement"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959"},{"key":"e_1_2_8_29_1","unstructured":"DiBenedettiD SlotaC WronskiS HauberB Assessing What Matters Most to Patients With or at Risk for Alzheimer's and Care Partners: Phase 1 Qualitative Interviews.Final Report. RTI Health Solutions;2019."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-010-0102-1"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.072983"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000342119"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.123"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01412-z"},{"key":"e_1_2_8_35_1","unstructured":"vanDyckCH Lecanemab for the treatment of early Alzheimer's disease: the extension of efficacy results from CLARITY AD.Presented at the 18th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders.Lisbon Portugal. March 5\u20109 2024.2024."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T11:22:24Z","timestamp":1760008944000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/alz.70224"],"URL":"https:\/\/doi.org\/10.1002\/alz.70224","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2024-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70224"}}